| Literature DB >> 31796467 |
Lin Ji1, Zengchao Liu2, Bin Zhou3, Ying Cai4, Fangmei An1, Lei Wang1, Zhifa Lv1, Min Xia1, Jianbo Yang2, Jianfen Yuan2, Hui Wang1, Zhiyi Zhou4, Shudong Yang4, Lei Hu2, Qiang Zhan5.
Abstract
A majority of gastric cancer cases in China are diagnosed at advanced stages, chiefly due to lack of an established routine nationwide screening program. This study evaluated the effectiveness of a novel screening program for gastric cancer. Seven geographic communities were randomly selected, and residents ages 40-69 years were screened. Serologic tests of Helicobacter pylori antibodies and pepsinogens, and positive family history of gastric cancer in first-degree relatives (FDR), were used to differentiate individuals for further gastroscopic examination and gastric mucosal biopsies. Among 7,773 individuals who underwent examination of serum markers, gastric cancer was detected in 14 (1.8%; 10 men). The rate in terms of gastric cancer cases per 100 gastroendoscopies was 1.6% (14/872), which was greater than 0.87% previously reported. Eleven of 14 patients with gastric cancer (78.6%) were FDRs of patients with gastric cancer. Two-thirds of the subjects with cardia gastric cancer were FDRs of individuals with gastric cancer rather than cardia gastric cancer. Comparative analysis indicated that the gastric cancer subjects were significantly more likely to be FDRs of patients with gastric cancer, in contrast to those without gastric cancer. All the individuals with gastric cancer were aged ≥50 years. After conducting a reverse analysis, we propose a novel screening program for gastric cancer. In conclusions, the populations most vulnerable to gastric cancer are those with positive family history of gastric cancer in FDRs, male gender, and aged 50 years or older. This screening program using fewer serum markers combined individual risk factors, mainly FDRs, is novel for identification of high-risk individuals for further gastroscopy in detecting early gastric cancer. ©2019 American Association for Cancer Research.Entities:
Mesh:
Year: 2019 PMID: 31796467 DOI: 10.1158/1940-6207.CAPR-19-0372
Source DB: PubMed Journal: Cancer Prev Res (Phila) ISSN: 1940-6215